The Payer License Agreement, or “Netflix Model,” for Hepatitis C Virus Therapies Enables Universal Treatment Access, Lowers Costs and Incentivizes Innovation and Competition
Summary High unit prices of treatments limit access. For epidemics like that of hepatitis C virus (HCV), reduced treatment access increases prevalence and incidence, making the infectious disease increasingly difficult to manage. The objective of the current study was to construct and test an alternative pricing model, the Payer License Agreement (PLA), and determine whether […]
English 
Spanish 
French 
Russian 
Arabic